Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2016 - 2017)

Crescent Biopharma (CBIO) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $726986.0 as the latest value for Q3 2017.

  • Quarterly Non-Current Deffered Revenue fell 13.6% to $726986.0 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $726986.0 through Sep 2017, down 13.6% year-over-year, with the annual reading at $753579.0 for FY2016, 209.29% up from the prior year.
  • Non-Current Deffered Revenue for Q3 2017 was $726986.0 at Crescent Biopharma, down from $742584.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $841426.0 in Q3 2016, with the low at $9709.0 in Q3 2014.
  • Average Non-Current Deffered Revenue over 5 years is $375778.5, with a median of $243647.0 recorded in 2015.
  • The sharpest move saw Non-Current Deffered Revenue dropped 27.5% in 2015, then soared 2739.56% in 2016.
  • Over 5 years, Non-Current Deffered Revenue stood at $96756.0 in 2013, then grew by 0.26% to $97012.0 in 2014, then surged by 151.15% to $243647.0 in 2015, then skyrocketed by 209.29% to $753579.0 in 2016, then fell by 3.53% to $726986.0 in 2017.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $726986.0, $742584.0, and $754055.0 for Q3 2017, Q2 2017, and Q1 2017 respectively.